Baxter International (BAX)
(Delayed Data from NYSE)
$37.54 USD
+1.05 (2.88%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $37.40 -0.14 (-0.37%) 7:58 PM ET
3-Hold of 5 3
A Value F Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$37.54 USD
+1.05 (2.88%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $37.40 -0.14 (-0.37%) 7:58 PM ET
3-Hold of 5 3
A Value F Growth C Momentum C VGM
Zacks News
Headquartered in Deerfield, IL, Baxter International Inc. (BAX) is a global medical technology company. However, the company spun off its biopharmaceuticals segment into an independent entity – Baxalta Inc. Following the spinoff, the company consists of renal and hospital products, providing items such as kidney-dialysis equipment, infusion pumps, and intravenous (IV) solutions.
Baxter International (BAX) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Baxter (BAX) delivered earnings and revenue surprises of 0.97% and 4.63%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
BAX vs. SYK: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
BAX vs. SYK: Which Stock Is the Better Value Option?
Baxter (BAX) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Baxter's (BAX) fourth-quarter results are likely to reflect growth in its Acute Therapies business.
DexCom (DXCM) Q4 Earnings Miss, Revenues Beat Estimates
by Zacks Equity Research
DexCom's (DXCM) fourth-quarter results benefit from domestic and international revenue growth and solid new customer additions.
DaVita's (DVA) Q4 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
DaVita's (DVA) strength in dialysis patient service revenues drives its Q4 top line.
Baxter International (BAX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Baxter (BAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Baxter (BAX) Hits 52-Week High: What's Aiding the Stock?
by Zacks Equity Research
Investors are optimistic about Baxter's (BAX) strong product portfolio.
Why Baxter (BAX) Could Beat Earnings Estimates Again
by Zacks Equity Research
Baxter (BAX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
3 Medical Products Stocks Poised to Beat This Earnings Season
by Trina Mukherjee
The Medical Products companies' Q4 results are likely to reflect base business recovery. Let's see how BAX, HSIC, and XRAY are poised ahead of their earnings releases.
Is Baxter International (BAX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Baxter International (BAX) and Gamida Cell (GMDA) have performed compared to their sector so far this year.
BD (BDX) Beats on Q1 Earnings and Revenues, Raises FY22 View
by Zacks Equity Research
The majority of BD's (BDX) core units witness strong revenue growth in the fiscal first quarter.
Abiomed (ABMD) Beats on Q3 Earnings, Narrows FY22 Guidance
by Zacks Equity Research
Abiomed's (ABMD) strength in Impella product revenues drives its Q3 top line.
McKesson (MCK) Earnings and Revenues Beat Estimates in Q3
by Zacks Equity Research
McKesson's (MCK) fiscal third-quarter 2022 results benefit from considerable growth across all segments.
Change Healthcare (CHNG) Q3 Earnings in Line, Revenues Beat
by Zacks Equity Research
Change Healthcare's (CHNG) fiscal third-quarter results benefit from solid performance across Software and Analytics, Network Solutions and Technology-Enabled segments.
Cardinal Health (CAH) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Cardinal Health's (CAH) fiscal second-quarter results benefit from a solid performance in the Pharmaceutical segment.
Boston Scientific (BSX) Q4 Earnings Top Estimates, Margins Up
by Zacks Equity Research
Boston Scientific (BSX) registers a year-over-year improvement in organic sales, indicating a strong rebound in legacy business from pandemic mayhem.
AmerisourceBergen (ABC) Q1 Earnings Lag Estimates, Revenues Beat
by Zacks Equity Research
AmerisourceBergen's (ABC) fiscal first-quarter results benefit from segmental growth.
PerkinElmer (PKI) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
PerkinElmer's (PKI) fourth-quarter results benefit from solid performance at Discover & Analytics Solutions business.
Catalent (CTLT) Q2 Earnings Top Estimates, FY22 View Up
by Zacks Equity Research
Catalent's (CTLT) robust performance across most of its segments drives its second-quarter fiscal 2022 top line.
Quest Diagnostics (DGX) COVID Test Sales Aid Amid Price Woe
by Zacks Equity Research
Quest Diagnostics' (DGX) base business continues to improve, signifying the ongoing recovery trend of the industry.
NextGen's (NXGN) Integrated Platform to Enhance Tribal Health
by Zacks Equity Research
NextGen's (NXGN) integrated platform was adopted by a community health center in Northern California to meet the health requirements of American Indians/Alaska Natives.
CVS Health (CVS) Hits a 52-Week High: What's Driving It?
by Zacks Equity Research
Strength across the retail segment and growing specialty pharmacy revenues are driving CVS Health's (CVS) top line.
Thermo Fisher (TMO) Base Sales Rebound, Bioproduction in Focus
by Zacks Equity Research
Thermo Fisher (TMO) is currently expanding its bioproduction purification resin capacity, which is used in the mRNA manufacturing process.
Here's Why You Should Invest in Henry Schein (HSIC) Now
by Zacks Equity Research
Investors are optimistic about Henry Schein's (HSIC) strong segmental performance and raised 2021 EPS guidance.
The Zacks Analyst Blog Highlights: Roche Holding, Pfizer, Baxter International, STMicro and Philips
by Zacks Equity Research
Roche Holding, Pfizer, Baxter International, STMicro and Philips are included in this analyst blog.